BioNTech Starts Dosing In Mid-Stage Melanoma Vaccine Trial
BioNTech SE (NASDAQ:BNTX) has dosed the first patient in its Phase 2 trial evaluating the BNT111 cancer vaccine. The study evaluates…
Sanofi Scores FDA Approval For Flu-Shot Facility In US
The FDA has approved Sanofi SA’s (NASDAQ:SNY) newly completed plant in Swiftwater, Pennsylvania. The license will allow Sanofi to begin production…
Sanofi’s Sutimlimab Hits Endpoint Goal In Rare Anemia Study After FDA Rejection
Sanofi SA’s (NASDAQ:SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold…
Sanofi Inks Partnership for Late-Stage Trial of Amcenestrant as Add-On Breast Cancer Therapy
Sanofi SA (NASDAQ:SNY) has secured partners for a Phase 3 trial to study amcenestrant versus the hormone therapy tamoxifen in breast…
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 3)
Sanofi Stops Venglustat Development In Rare Genetic Kidney Disorder
Sanofi SA (NASDAQ:SNY) has halted the clinical program of venglustat in autosomal dominant polycystic kidney disease (ADPKD). Although the safety profile…
Regeneron and Sanofi Announced Libtayo Received Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
Regeneron Pharmaceuticals, Inc.
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving broadly lower for much of the week before coming back up strongly in the final session. Some of the weakness may be traced back to the across-the-board weakness in markets, as macroeconomic fears unnerved traders.
15 European Dividend Aristocrats To Diversify Your Portfolio
In general, Dividend Aristocrats are the foundation for the portfolios of most serious dividend growth investors. European Dividend aristocrats are typically blue chip stocks that have proven to reward shareholders with rising dividends over a long period.